Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSP191 Conditioning for HCT in SCID
NCT02963064Phase 2Terminated
- Sponsor
- Jasper Therapeutics, Inc.
- Start
- Mar 2017
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of briquilimab in severe combined immunodeficiency (SCID), sponsored by Jasper Therapeutics, Inc. Primary endpoints: Safety and tolerability of JSP191 as conditioning therapy, Efficacy of JSP191 as conditioning therapy (Engraftment) and 1 more. Started Mar 2017; status: terminated.
02
Drugs
briquilimab
03
Conditions
severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NCT02963064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963064.